OmniAb, Inc. (NASDAQ:OABI - Get Free Report) insider Charles S. Berkman sold 7,206 shares of the business's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $2.00, for a total transaction of $14,412.00. Following the sale, the insider now owns 363,212 shares of the company's stock, valued at approximately $726,424. This represents a 1.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
OmniAb Price Performance
NASDAQ OABI opened at $2.09 on Tuesday. The firm has a market cap of $255.26 million, a PE ratio of -3.37 and a beta of 0.06. OmniAb, Inc. has a 52 week low of $1.90 and a 52 week high of $5.45. The company has a 50 day moving average price of $3.14 and a 200 day moving average price of $3.61.
OmniAb (NASDAQ:OABI - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. The firm had revenue of $10.80 million for the quarter, compared to analyst estimates of $10.13 million. During the same period in the previous year, the company earned ($0.14) earnings per share. On average, equities research analysts anticipate that OmniAb, Inc. will post -0.61 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently commented on OABI. Royal Bank of Canada decreased their price objective on OmniAb from $7.00 to $4.00 and set an "outperform" rating on the stock in a research note on Thursday, March 27th. Benchmark dropped their price objective on shares of OmniAb from $8.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of OmniAb in a report on Wednesday, March 19th.
Get Our Latest Analysis on OABI
Institutional Trading of OmniAb
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in OmniAb by 3.3% during the fourth quarter. Invesco Ltd. now owns 93,653 shares of the company's stock valued at $332,000 after purchasing an additional 2,997 shares in the last quarter. Connors Investor Services Inc. boosted its stake in OmniAb by 18.4% during the fourth quarter. Connors Investor Services Inc. now owns 29,611 shares of the company's stock worth $105,000 after buying an additional 4,611 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of OmniAb by 16.5% in the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company's stock valued at $144,000 after purchasing an additional 5,751 shares during the period. Sherbrooke Park Advisers LLC grew its stake in shares of OmniAb by 53.5% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company's stock valued at $61,000 after buying an additional 6,001 shares during the period. Finally, Isthmus Partners LLC grew its position in OmniAb by 1.6% in the fourth quarter. Isthmus Partners LLC now owns 453,135 shares of the company's stock worth $1,604,000 after acquiring an additional 7,001 shares during the period. Institutional investors and hedge funds own 72.08% of the company's stock.
About OmniAb
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
